CORPORATE PROFILE

 

We are late pre-clinical stage oncology drug development company developing new revolutionary therapies against cancer and diabetes. We have a vision of changing cancer treatment, addressing resistance development, metastasis, and patient relapse. Felicitex owns proprietary sets of clinical candidates: selective and specific small molecule inhibitors.​Principals have unique expertise in the development of cancer therapeutics, extensive Pharma and business development experience. Felicitex has developed multiple collaborations with leading academic and commercial institutions.